Please login to the form below

Not currently logged in
Email:
Password:

autoimmune conditions

This page shows the latest autoimmune conditions news and features for those working in and with pharma, biotech and healthcare.

Syncona launches another cell therapy company, Treg specialist Quell

Syncona launches another cell therapy company, Treg specialist Quell

of solid organ transplant and autoimmune conditions. ... Previous deals saw Celgene swoop on Delinia and its Treg therapies for autoimmune conditions, paying $300m upfront for the company, while Eli Lilly paid $150m for co-development rights to a

Latest news

More from news
Approximately 2 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Managing medication non-adherence Managing medication non-adherence

    Autoimmune conditions such as Crohn’s disease can flare up through an imbalance of things like stress, lack of sleep or overworking - not just as a direct consequence of nonadherence to ... The latter is a vital service for patients with chronic

  • Taking a lean and careful approach Taking a lean and careful approach

    This fits well with our mission to tackle unmet needs. Autoimmune conditions are increasing and diabetes is at epidemic levels. ... A lot of NASH patients also have these conditions so we want to look at and understand the underlying causes to see what

  • Deal Watch table for April 2014 Deal Watch table for April 2014

    7, 100. Questcor/ Mallinckrodt. Acquisition. Acthar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions.

  • Pharma deals during April 2014 Pharma deals during April 2014

    premium. This gives Mallinckrodt, Acthar Gel (repository corticotropin), which is FDA approved for 19 “difficult-to-treat” autoimmune and inflammatory associated conditions and currently primarily used to treat multiple sclerosis relapses,

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    165. Novartis / Questcor. Development rights. Rights to develop Synacthen (tetracosactide,   melanocortin receptor agonist) and Synacthen Depot (approved in Europe for autoimmune &inflammatory conditions).

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Patient Persepective: Autoimmune Disease

    Autoimmune diseases affect 1–5% of the World’s population and have varied symptoms and causes. ... Here we explore with Lois what it is like to live with the symptoms of autoimmune disease, including Crohn’s disease, a form of inflammatory bowel

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...
Investing in our People
As a small, boutique agency we can and do invest heavily in our team, who produce amazing results for our clients....

Infographics